Interview: John Sampalis – President & CEO, JSS, Canada
Dr. John Sampalis, CEO of JSS talks about the impact that changes in the global R&D landscape have had on JSS, the role technology is playing in running an efficient…
Clementia is charting a new course to develop effective new treatments for people who have none.
The company is developing its lead candidate palovarotene, a novel RARγ agonist, to treat Fibrodysplasia Ossificans Progressiva (FOP), Multiple Osteochondromas (MO), and other diseases.
We believe that palovarotene holds significant potential for individuals with debilitating bone and other diseases with high unmet medical need.
Our name, Clementia, is derived from the Latin word for compassion or empathy – a concept that inspires everything we do.
Contact:
Address: 4150 Ste-Catherine Street West, Suite 550, Montreal, QC H3Z 2Y5, Canada
Tel.: +1 (514) 940-3600
Website: http://clementiapharma.com/
Dr. John Sampalis, CEO of JSS talks about the impact that changes in the global R&D landscape have had on JSS, the role technology is playing in running an efficient…
Mark Nawacki, CEO and co-founder of Searchlight Pharma, affirms the company’s dedication to women’s health through a modern approach to current market trends. He underlines the company’s commitment to productive…
Dr. Janice E. Parente, president and founder of ethica CRO, explains what led her company to work with pharmaceutical companies internationally and how ethica CRO’s accreditations are an emblem of…
Linda Tibbits, general manager at Pierre Fabre Dermo-Cosmetics in Canada takes us back to the beginnings of the French company in the country, where its initial success was driven by…
Colette Rivet, executive director of the Cannabis Canada Association, leading Canadian licensed medical cannabis producers, talks regulatory challenges, upcoming opportunities, export ambitions and collaboration with the provincial and federal government…
Dr. Brian O’Rourke, president and CEO of CADTH, presents the organization’s main programs and the strategies it has put in place in order to ensure excellence in the future as…
Michael Rudnicki, chair of the Regenerative Medicine Alliance of Canada (RMAC) discusses the mandate of the newly established organization, the exciting potential of regenerative medicine, and Canada’s competitive edge in…
John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable enterprise with FDA approved products that are being…
Brian Lewis, president and CEO of MEDEC, speaks towards the importance of building a strong medical device ecosystem and the association’s collaboration with industry stakeholders to push advancements in terms…
Quebec’s Deputy Premier and Minister of Economy, Science and Innovation Dominique Anglade, who is also the Minister responsible for the Digital Strategy, shares the strategic significance of her portfolios to…
Michel Charbonneau, executive VP at Accord Healthcare Inc. touches upon the rapid evolution of the Canadian affiliate over the past five years, and the company’s commitment to bringing high-quality, innovative,…
Louis Pilon, president and CEO, highlights JAMP Pharma’s unique positioning as a Canadian generics company with one of the largest salesforce covering the whole Canadian market as well as the…
See our Cookie Privacy Policy Here
